Showing posts with label arbovirus. Show all posts
Showing posts with label arbovirus. Show all posts

Wednesday, 8 January 2025

Assessing the Prevalence and Seroprevalence of Acute Dengue and Chikungunya Virus Infections from Theni, Tamil Nadu, India: A Retrospective Hospital-Based Study | Chapter 8 | Medical Research and Its Applications Vol. 1

 

The purpose of this study was to assess the prevalence and seroprevalence of acute dengue and chikungunya virus infections, as well as their co-infections. Viral-borne diseases have recently gained significant public health importance in the current world. Chikungunya disease has been documented in non-endemic countries, despite the fact that CHIKV has largely been detected in underdeveloped countries, suggesting the possibility of ongoing transmission to new locations. The Viral Research and Diagnostic Laboratory (VRDL) located at Government Theni Medical College (GTMC), Theni, Tamil Nadu conducts the diagnosis of common virus infections. The present study was a retrospective study conducted at the Viral Research and Diagnostics Laboratory (VRDL) located at a tertiary care hospital, in Theni, India from January 2018 to June 2023. DENV and CHIKV were detected using an enzyme-linked immunosorbent assay (ELISA) in all of the samples. This study included 16,997 cases, with 11264/2971 (26.3%) testing positive for Dengue IgM, 1395/288 (20.6%) for Dengue NS1 Ag, 19/3 (15.7%) for IgG, and 4319/3388 (8.9%) for CHIKV IgM. Fever (n = 16598, 97.6%) was the most prevalent clinical characteristic in all probable dengue and chikungunya patients. Other symptoms were chills (n = 11252, 66.1%), arthralgia (n = 10245, 60.2%), headache (n = 11354, 66.8%), and joint pain (n = 11256, 66.2%). The results demonstrated a lower probability of obtaining both DENV and CHIKV infections at the same time, although the risk is still not negligible. This study looks into the clinical appearance of suspected Dengue-Chikungunya patients. The increased frequency of Dengue and Chikungunya, as well as their co-infection, demands close monitoring of endemic regions and effective patient care management. Understanding the prevalence of Dengue-Chikungunya infection in this area will be easier with a longer time horizon, a larger sample size, and information on the co-infection status. Taking all of these aspects into account, prompt and effective treatment can aid in the prediction and control of viral epidemics.

 

Author (s) details:-

 

R. Gopinath
Department of Microbiology, Govt. Theni Medical College, Theni, Tamil Nadu-625512, India.

 

M. Arundadhi
Department of Microbiology, Govt. Theni Medical College, Theni, Tamil Nadu-625512, India.

 

A. Dhanasezhian
Department of Microbiology, Govt. Theni Medical College, Theni, Tamil Nadu-625512, India.

 

M. Sowndarya
Department of Microbiology, Govt. Theni Medical College, Theni, Tamil Nadu-625512, India.

 

Daya Pauline S.
Department of Microbiology, Govt. Theni Medical College, Theni, Tamil Nadu-625512, India.

 

G. Sucila Thangam
Department of Microbiology, Govt. Theni Medical College, Theni, Tamil Nadu-625512, India.

 

Please See the book here :-  https://doi.org/10.9734/bpi/mria/v1/307

Thursday, 16 September 2021

Study on Mayaro Virus Disease: Symptoms and Treatments | Chapter 10 | Innovations in Microbiology and Biotechnology Vol. 1

The goal of this chapter was to go over the various features of fever induced by the Mayaro virus, including symptoms, aetiology, therapy, and diagnosis. Mayaro virus causes a vague, sublethal disease in humans, with symptoms similar to chikungunya, dengue fever, and other viruses. Arthralgia symptoms, which are frequently connected with viral infections, can be incapacitating. Since initial isolation in 1954 [Trinidad and Tobago], outbreaks have been confined and infrequent inside the Pan-Amazonia forest. As a result, the literature available is diverse, sparse, and dispersed. Mayaro virus is an alphavirus that is connected to the Semliki forest antigenic complex phylogenetically. Mayaro and the related UNA viruses are the only members of this group that have been identified in the New World. Mayaro's genome is made up of 12 kb of single-stranded positive-charged RNA that can be separated into genomic and subgenomic areas that encode nonstructural and structural proteins, respectively. Mayaro has demonstrated great adaptability in vertebrate hosts for infections, but high selectivity invertebrates for the Culicidae [mosquito] family. Forested environments in northern South America, as well as the rainy season, are risk factors for disease. MAYV has two genotypes: L [limited to Belterra, Brazil] and D [widely dispersed throughout Pan-Amazonia]. The enzootic cycle is analogous to the yellow fever jungle cycle, in which Haemagogus mosquitoes and monkeys serve as reservoirs. Other secondary vectors and hosts, such as Aedes aegypti, Aedes albopictus, and Aedes scapularis, have been demonstrated experimentally to transmit the virus efficiently, and this poses a threat to the virus's spread. Due to the high viremia levels of infected people, there is a major risk of an emergent disease in urban, rural, and peridomestic areas around Mayaro virus enzootic foci.

Author (S) Details

Salvatore G. De-Simone
FIOCRUZ/Center for Technological Development in Health [CDTS]/National Institute of Science and Technology in Neglected Disease Innovation [INCT-IDN], Rio de Janeiro, RJ, Brazil. and Federal Fluminense University, Department of Cell and Molecular Biology, Niterói, RJ, Brazil.

Paloma Napoleão-Pego
FIOCRUZ/Center for Technological Development in Health [CDTS]/National Institute of Science and Technology in Neglected Disease Innovation [INCT-IDN], Rio de Janeiro, RJ, Brazil.

Larissa Rodrigues Gomes
FIOCRUZ/Center for Technological Development in Health [CDTS]/National Institute of Science and Technology in Neglected Disease Innovation [INCT-IDN], Rio de Janeiro, RJ, Brazil.

Guilherme C. Lechuga
FIOCRUZ/Center for Technological Development in Health [CDTS]/National Institute of Science and Technology in Neglected Disease Innovation [INCT-IDN], Rio de Janeiro, RJ, Brazil.

David W. Provance-Jr
FIOCRUZ/Center for Technological Development in Health [CDTS]/National Institute of Science and Technology in Neglected Disease Innovation [INCT-IDN], Rio de Janeiro, RJ, Brazil.

View Book :- https://stm.bookpi.org/IMB-V1/article/view/3768